Tag: option

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

ALBUQUERQUE, N.M., June 24, 2025 (GLOBE NEWSWIRE) -- Array Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced that it has priced an upsized offering of $300 million in aggregate principal amount of 2.875% convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). ARRAY has also granted the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period from, and including the date on which the Notes are first issued, up to an additional $45 million in aggregate principal amount of Notes. The Offering is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.

LED-Based Skincare Device Highlighted for Non-Invasive Anti-Aging and Acne Support Backed by Clinical Usage Data

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.

Plant-Based Ingredients, Scientific Research, and Mineral Synergy Come Together in This Modern Approach to Natural Weight Support

VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or the “Company”) is pleased to announce it has successfully completed the renewal and amendment (the “Amended Revolving Facility”) of its existing revolving credit facility resulting in an $80 million revolving credit facility. The Amended Revolving Facility provides the Company with $35 million of incremental borrowing capacity, consisting of $10 million of expanded revolving credit capacity with CIBC and the introduction of $25 million of incremental revolving credit capacity with Rabobank. The Amended Revolving Facility has a maturity date of June 23, 2027, and replaces the Company's current credit facilities with CIBC, which matures on October 19, 2025. The new agreement includes an option to extend maturity by one year, to June 23, 2028.

Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held

WOODLAND PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced fiscal 2025 fourth quarter and full fiscal year financial results and filed its 10-K for the year ended March 31, 2025. The Company also issued an update on its Demonstrated Intent metric which can be found on Anterix’s website at https://investors.anterix.com/events-presentations.